Pharmacoeconomic analysis of the application of strong opioids for the treatment of chronic pain syndrome in patients with pancreatic cancer
Abstract
Objective: to evaluate the clinical and economic feasibility of opioid therapy based on the analysis of its cost and effectiveness in patients with chronic pain syndrome in pancreatic cancer.
Material and methods. An observational prospective study in parallel groups of patients with chronic pain syndrome associated with pancreatic cancer was carried out. The analysis of cost minimization and cost-effectiveness was applied, as well as pharmacoeconomic modeling, which included the construction of a decision tree in patients receiving morphine sulfate (n=45) and fentanyl TTS (n=45) for pain relief. The sensitivity of the obtained data was assessed using one-way analysis.
Results. It was shown that the treatment of chronic pain syndrome in patients with pancreatic cancer with opioid analgesics as part of combined treatment is the least expensive in the morphine sulfate group (incremental cost-effectiveness ratio 144.93). Based on the results of modeling, the prognostic factors of influence on the cost of analgesic therapy were determined: the cost of combined analgesic therapy, the cost of treatment of adverse reactions, and the cost-effectiveness ratio.
Conclusion. Analgesic therapy of chronic pain syndrome with morphine sulfate in patients with pancreatic cancer is pharmacoeconomically feasible.
About the Authors
O. P. Bobrova
Voino-Yasenetsky Krasnoyarsk State Medical University; Kryzhanovskiy Krasnoyarsk Regional Clinical Oncological Dispensary
Russian Federation
Russian Federation
Olga P. Bobrova – MD, PhD, Associate Professor, Chair of Pharmacology and Pharmaceutical Consulting with Postgraduate Education Course; Clinical Pharmacologist
Scopus Author ID: 57200543078; RSCI SPIN-code: 3525-8218
1 Partizan Zheleznyak Str., Krasnoyarsk 660022, Russia
16 Pervaya Smolenskaya Str., Krasnoyarsk 660133, Russia
S. K. Zyryanov
Peoples’ Friendship University of Russia; City Clinical Hospital No. 24
Russian Federation
Russian Federation
Sergey K. Zyryanov – Dr. Med. Sc., Professor, Chief of Chair of General and Clinical Pharmacology; Deputy Chief Physician for Therapy
Scopus Author ID: 35796816700; RSCI SPIN-code: 2725-9981
10 corp. 3 Miklukho-Maklay Str., Moscow 117198, Russia
10 Pistsovaya Str., Moscow 127015, Russia
N. A. Shnayder
Voino-Yasenetsky Krasnoyarsk State Medical University; Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation
Russian Federation
Natalia A. Shnayder – Dr. Med. Sc., Professor, Leading Researcher, Center of Collective Usage “Molecular and Cellular Technologies”; Leading Researcher, Department of Personalized Psychiatry and Neurology
WoS ResearcherID: M-7084-2014; RSCI SPIN-code: 1952-3043
1 Partizan Zheleznyak Str., Krasnoyarsk 660022, Russia
3 Bekhtereva Str., Saint Petersburg 192019, Russia
M. M. Petrova
Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
Russian Federation
Marina M. Petrova – Dr. Med. Sc., Professor, Head of Department of Polyclinic Therapy, Family Medicine and Healthy Lifestyle with Postgraduate Education
Course
WoS ResearcherID: L-5623-2014; Scopus Author ID: 23987271200; RSCI SPIN-code: 3531-2179
1 Partizan Zheleznyak Str., Krasnoyarsk 660022, Russia
References
1. Cancer today. Data visualization tools for exploring the global cancer burden in 2020. Available at: https://gco.iarc.fr/today/home (accessed 23.06.2021).
2. Kimura K., Amano R., Nakata B., Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma. World J Surg Oncol. 2014; 12: 360. https://doi.org/10.1186/1477-7819-12-360.
3. Kneuertz P.J., Cunningham S.C., Cameron J.L., et al. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg. 2011; 15 (11): 1917–27. https://doi.org/10.1007/s11605-011-1665-9.
4. Palliative care for adults: strong opioids for pain relief. Clinical guideline. Available at: https://www.nice.org.uk/guidance/CG140 (accessed 23.06.2021).
5. Dale O., Moksnes K., Kaasa S. European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med. 2011; 25 (5): 494–503. https://doi.org/10.1177/0269216310384902.
6. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs; 2012; 72 (2): 181–90. https://doi.org/10.2165/11597260-000000000-00000.
7. Muralidharan A., Smith M.T. Pain, analgesia and genetics. J Pharm Pharmacol. 2011; 63 (11): 1387–400. https://doi.org/10.1111/j.2042-7158.2011.01340.x.
8. Petrova M.M., Shnayder N.A., Pronina E.A., Bobrova O.P. Diagnosis of neuropathic pain: scales and questionnaires. Siberian Medical Review. 2020; 3: 61–9 (in Russ.). https://doi.org/10.20333/2500136-2020-3-61-69.
9. Methodological guidelines. Determination of the degree of reliability of the causal relationship “Adverse side reaction – a drug” (classification and methods). Available at: https://docs.cntd.ru/document/499043554 (in Russ.) (accessed 23.06.2021).
10. Order of the Ministry of Health of the Russian Federation No. 163 dated 27.05.2011 “On approval of the industry standard" Clinical and Economic Research. General provisions”. Available at: https://docs.cntd.ru/document/901823470 (in Russ.) (accessed 23.06.2021).
11. The State Register of maximum manufacturers’ selling prices for drugs included in the list of vital and essential. Available at: https://minzdrav.gov.ru/opendata/7707778246-gosreestrpredelnyhotpusknyhcen/visual (in Russ.) (accessed 23.06.2021).
12. Kulikov A.Yu., Nguyen T.T., Tikhomirova A.V. Modeling methodology in pharmacoeconomics. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2011; 4 (4): 8–17 (in Russ.).
13. Glagolev M.V. Sensitivity analysis of the model. Environmental Dynamics and Global Climate Change. 2012; 3 (3): 31–53 (in Russ.).
For citation:
Bobrova O.P., Zyryanov S.K., Shnayder N.A., Petrova M.M. Pharmacoeconomic analysis of the application of strong opioids for the treatment of chronic pain syndrome in patients with pancreatic cancer. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(3):281-290. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.080
Views: 109
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 